Cleared Traditional

K850458 - DUPONT DIGOXIN ASSAY REAGENTS

K850458 is the FDA 510(k) clearance for DUPONT DIGOXIN ASSAY REAGENTS by E.I. Dupont DE Nemours & Co., Inc.. It is a Class 2 Toxicology device (product code KXT) cleared through the Traditional 510(k) pathway after a 27-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1985
Decision
27d
Days
Class 2
Risk

K850458 is an FDA 510(k) clearance for the DUPONT DIGOXIN ASSAY REAGENTS. Classified as Enzyme Immunoassay, Digoxin (product code KXT), Class II - Special Controls.

Submitted by E.I. Dupont DE Nemours & Co., Inc. (Wilmington, US). The FDA issued a Cleared decision on March 5, 1985 after a review of 27 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3320 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all E.I. Dupont DE Nemours & Co., Inc. devices

Submission Details

510(k) Number K850458 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 06, 1985
Decision Date March 05, 1985
Days to Decision 27 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
60d faster than avg
Panel avg: 87d · This submission: 27d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KXT Enzyme Immunoassay, Digoxin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3320
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - KXT Enzyme Immunoassay, Digoxin

All 69
Devices cleared under the same product code (KXT) and FDA review panel - the closest regulatory comparables to K850458.
EMIT DIGOXIN MOBILE PHASE SOLUTION
K861394 · Syva Co. · May 1986
CEDIA DIGOXIN ASSAY
K854638 · Microgenics Corp. · Mar 1986
COBAS FP REAGENTS FOR DIGOXIN & COBAS FP DIGOXIN C
K851032 · Roche Diagnostic Systems, Inc. · Apr 1985
EPSILON DIGOXIN TEST KIT
K842655 · Beckman Instruments, Inc. · Aug 1984
OPTIMATE DIGOXIN TEST
K841582 · Miles Laboratories, Inc. · May 1984
ACA DIGOXIN ANALYTICAL TEST PACK
K841107 · E.I. Dupont DE Nemours & Co., Inc. · Apr 1984